Topical Mitogenic-Activated Protein Kinase (MAPK) Inhibition in Rosacea

Inclusion Criteria: * Erythematotelangiectatic rosacea diagnosed by a clinician in the centrofacial and/or ocular regions. Exclusion Criteria: * Other concurrent diseases for which treatment is being received that would preclude the use of trametinib (i.e., pleural effusion, active infection, intracranial bleeding) * History of skin allergic reactions or documented allergic reaction to trametinib * Pregnancy or lactation. * Heart failure or other heart disease * Active use of medications with known documented interactions with trametinib (Chloroquine, Ritonavir, Loperamide, Penicillamine)